RecruitingNCT05154370

China National Registry of Neuro-Inflammatory Diseases

China National Registry of Neuro-Inflammatory Diseases: a Prospective Cohort Study


Sponsor

Beijing Tiantan Hospital

Enrollment

10,000 participants

Start Date

Dec 15, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

Central nervous system (CNS) idiopathic inflammatory demyelinating diseases (IDD) are mainly diseases caused by autoimmune factors that result in CNS demyelination damage and loss. It tends to accumulate in the brain, spinal cord and optic nerves. Multiple sclerosis (MS), clinically isolated syndrome (CIS), neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and acute disseminated encephalomyelitis (ADEM) are all common IDDs of the CNS. Besides, primary angiitis of the central nervous system (PACNS), autoimmune glial fibrillary acidic protein astrocytopathy (GFAP-A), etc. may also be included because they are important differential diagnoses. This study will establish a large prospective cohort study database of Chinese IDD, which will record detailed electronic information on IDD patients, including demographic and socioeconomic data, medical history, clinical information, medication, and relevant examination results. The long-term observational study will be used to understand the natural history of disease, disability progression rates, imaging and biological indicators, long-term treatment approaches and prognosis of Chinese patients with IDD, to find predictive markers for IDD progression and prognosis, and to identify factors that influence the treatment and prognosis of patients with IDD.


Eligibility

Plain Language Summary

Simplified for easier understanding

This study is creating a national registry in China for patients with neuroinflammatory (neuro-immune) diseases — conditions where the immune system attacks the nervous system. These include multiple sclerosis, neuromyelitis optica, and related disorders. The registry will help researchers track how these diseases progress and respond to treatment over time. **You may be eligible if...** - You have been diagnosed with at least one of the following: clinically isolated syndrome (CIS), multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), MOG antibody-associated disease (MOGAD), or acute disseminated encephalomyelitis (ADEM) - You are able and willing to sign an informed consent form - There is no age or gender restriction **You may NOT be eligible if...** - You have a severe mental illness that prevents you from cooperating with follow-up or examinations - You or your legal representative refuse to or cannot sign informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIntravenous steroid

This study does not limit treatment methods. Patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. Immunomodulatory therapies are necessary for the remission stage. All drugs are used in accordance with relevant guidelines.


Locations(1)

Beijing Tiantan Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05154370


Related Trials